Compare Dominion Energy Inc (D) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dominion Energy Inc vs Inovio Pharmaceuticals Inc — how do they compare? Dominion Energy Inc trades at $68.36 (market cap $59.06B), while Inovio Pharmaceuticals Inc trades at $0.78 (market cap $76.09M). The key difference: Dominion Energy Inc is far larger — about 776.2× Inovio Pharmaceuticals Inc's market cap, and Dominion Energy Inc pays a 3.98% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| D | INO | |
|---|---|---|
Market Cap | $59.06B | $76.09M |
Sector | Utilities | Health |
52-Week High | $71.67 | $2.87 |
52-Week Low | $57.08 | $0.66 |
Enterprise Value | $113.18B | $47.10M |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $67.39, up 0.88% today, with a bearish technical signal but strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.79, exceeding expectations, and maintains a stable dividend. Revenue growth is robust, rising to $16.51B in 2025, with a net income margin of 13.99%. Analyst consensus is mixed, with a $70.43 price target, but technical indicators show resistance near $68.
Outlook remains cautious due to high debt levels and bearish technicals, though fundamentals are solid with consistent profitability. Risks include regulatory pressures and capital expenditure demands. The stock offers income appeal with dividends, but near-term price action may face headwinds from technical selling pressure.
INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.
High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
